ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1101

COVID-19 Vaccination (VAX) and Infection (INF)-Related Glomerular Diseases (GNs)

Session Information

  • COVID-19 - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Pham, Phuong-Chi T., UCLA Medical Center Olive View, Sylmar, California, United States
  • Valluri, Vinod K., UCLA Medical Center Olive View, Sylmar, California, United States
  • Jafari, Golriz, UCLA Medical Center Olive View, Sylmar, California, United States
  • Kamarzarian, Anita, UCLA Medical Center Olive View, Sylmar, California, United States
  • Bath, Kulwant Singh, UCLA Medical Center Olive View, Sylmar, California, United States
  • Haghi, Masoud, UCLA Medical Center Olive View, Sylmar, California, United States
  • Pham, Phuong-Thu T., University of California Los Angeles, Los Angeles, California, United States
Background

There have been numerous reports of GNs associated with both COVID-19 VAX and INF. We performed a systematic review per PRISMA involving reported COVID-19 VAX and INF-associated GN cases to explore for supportive evidence of a cause-and-effect rather than a fortuitous relationship.

Methods

We searched NLM, EMBASE, and the World Health Organization COVID-19 database for case reports and series, and observational studies for reported VAX or INF-associated GNs.

Results

Of 1261 articles identified, 117 articles were included. Fifty-eight articles pertained to infection- and 59 to vaccine-related GNs. Among vaccine-related GNs, the top 3 diagnoses were IgA nephropathy (IgAN, 35 out of 111 cases, 31.5%), anti-neutrophil cytoplasmic antibody-associated GN (ANCA, 23 out of 111, 18.9%), and minimal change disease (MCD, 23 out of 111, 18.9%). Among infected patients, the top 3 were focal segmental glomerulosclerosis (FSGS, 90 out of 162, 55.6%), ANCA-associated GN (34 out of 162, 21.0%), and IgAN (12 out of 162, 7.4%). The distributive patterns of reported GNs associated with the VAX and INF differ significantly compared with that in the pre-COVID era, where excluding diabetic glomerulosclerosis, the top 3 GNs globally were FSGS 17.4%, IgAN 16.5%, and MN 12.1%.

Conclusion

Based on the pathogenesis of GNs and systemic immune response to COVID-19 VAX and INF and the observed differences in GN patterns among pre-COVID era, VAX, and INF-reported GN cases, we suspect that the relationship betweent VAX and INF-reported GNs were directly causal rather than coincidental.

GNPre-COVID global distribution (%)COVID-19 vaccine n (%)COVID-19 infection n (%)
Focal segmental glomerulosclerosis17.43 (2.7)90 (55.6)
IgA nephropathy/Henoch Schonlein purpura16.535 (31.5)12 (7.4)
Diabetic kidney disease13.90 (0)0 (0)
Membranous nephropathy12.110 (9)6 (3.7)
Lupus nephritis12.24 (3.6)1 (0.6)
ANCA6.221 (18.9)34 (21)
Minimal change disease5.221 (18.9)2 (1.2)
MPGN/C3GN33 (2.7)0 (0)
Renal amyloid2.91 (0.9)1 (0.6)
TTP/HUS2.54 (3.6)12 (7.4)
Others8.19 (8.1)4 (2.5)
Total100111 (99.9)162 (100)

Glomerular diseases reported following COVID-19 vaccination and infection in non-transplant patients.